Advertisement

Topics

Companies Related to "A Study of RO5045337 in Patients With Solid Tumors" [Most Relevant Company Matches] - Page: 4 RSS

20:01 EDT 18th March 2019 | BioPortfolio

Here are the most relevant search results for "A Study of RO5045337 in Patients With Solid Tumors" found in our extensive corporate database of over 50,000 company records.

Showing "Study RO5045337 Patients With Solid Tumors" Companies 76–100 of 4,700+

Relevant

Sensipar® (cinacalcet HCl)

Sensipar® (cinacalcet HCl) is an innovative, first-in-class, oral therapy indicated to treat hyperparathyroidism (excessive levels of parathyroid hormone) caused by chronic kidney disease; it is approved for use in patients who are receiving dialysis. It is also indicated to treat elevated calcium levels in patients with malignant tumors of the parathyroid gland.


Alfacell Corporation

Alfacell Corporation is a biopharmaceutical company primarily engaged in the discovery and development of a new class of anti-cancer drugs from amphibian ribonucleases ("RNases"). RNases degrade ribonucleic acids ("RNA") causing an interruption in protein synthesis resulting in inhibition of cell growth and induction of apoptosis (programmed cell death). The Company's first produ...

Eureka Therapeutics, Inc.

Eureka Therapeutics, Inc. is a privately held biotechnology company, headquartered in the San Francisco Bay area, focused on developing first-in-class T cell immunotherapies for hematological malignancies and solid tumors. Its core technology platforms center around the discovery and engineering of fully human antibodies against intracellular targets via t...


SharedClarity

SharedClarity is a unique joint effort between health care systems and UnitedHealthcare to use data from tens of millions of patients to study the long-term effectiveness of high-technology medical devices that have a high impact on patients. SharedClarity will use the results of the studies to select the best devices for patients and negotiate affordable ...

Amphivena Therapeutics Inc.

Amphivena Therapeutics, founded in 2013, is a private biotechnology company developing AMV654, a CD33/CD3-bispecific T cell engaging antibody for the treatment of AML, MDS and solid tumors. MPM Capital, Amphivena’s major shareholder, led a $19.5 M Series A financing, with participation by Aeris Capital and Affimed GmbH. More recently, funds managed by...

Foundation Medicine, Inc. and WuXi PharmaTech

Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sa...

Med Discovery SA

Med Discovery’s mission is the discovery and development of highly specific protein drugs to treat uro-genital cancers. By combining biological drug discovery expertise with a strong in-house knowledge of the medical urology field, the Company is uniquely positioned to develop novel drugs for urological cancers and other related solid tumors. Med Discovery wants to become a worldwide leading res...

C.P.M.

C.P.M. is one of the biggest pharmaceutical contract manufacturers in Germany. Besides the production of solid, semi-solid and fluid forms of administration, we can also handle the complete development and project management of your products through to validation

PreScience Labs, LLC

PreScience is a developmental stage bio-pharmaceutical company focused on the development of anti-cancer drugs. It has successfully completed preclinical mechanistic, in vitro and animal testing using intra-arterial delivery of its proprietary drug PSL-001. The FDA approved immediate enrollment of a Phase I, dose-escalating study, which PreScience intends ...

Epeius Biotechnologies Corp.

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems. Rexin-G is currently approved for the treatment of all chemotherapy-resistant solid tumors by the Philippine FDA. To learn more about our lead products a...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

North American Scientific

Our Mission To pursue with passion the development and introduction of innovative new products that empower physicians and patients with individualized, life-saving treatment solutions. Company Overview Little more than ten years ago, radiation oncology was as much a source of frustration as of hope for its dedicated professionals. Physicians had to face the fact that they often did more harm...

America Stem Cell, Inc.

America Stem Cell is a privately held biotechnology company based in San Antonio, TX, with offices in San Diego, CA, and is dedicated to the development and commercialization of stem cell enabling technologies/products to transform clinical outcomes for patients undergoing stem cell transplantation. The key stem cell enabling platform technologies/compound...

Protox Therapeutics Inc.

Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. Through the company’s INxin™ and PORxin™ technology platforms, therapeutic candidates are generated by engineering the naturally occurring toxins, Pseudomonas exotoxin and proaerolysin. These drug...

Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigat...

Nodality, Inc.

Nodality develops and commercializes the next generation of personal diagnostic tests by characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells. The South San Francisco based company applies proprietary multiparametric Single Cell Network Profiling (SCNP) technology to develop highly predictive biological ...

Novian Health Inc.

Novian Health Inc., located in Chicago, is a privately held company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy (ILT). The company’s minimally invasive Novilase procedure uses ILT (controlled heating) for the ablation of breast tumors as an alternative to the surgically invasive, traditional "lumpectomy."

S.T.A.R.S. Healthcare

S.T.A.R.S. Healthcare helps put people on the road to better health and better quality of life by providing superior sleep testing and respiratory services to patients in Arizona. At S.T.A.R.S. sleep centers, patients complete a comprehensive sleep study, obtain an expert diagnosis on a wide range of sleep disorders, and receive recommended treatment from ...

Autolus Therapeutics Limited

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer c...

Genosco

Located in Cambridge, MA, Genosco is a clinical-stage biotechnology company led by CEO, Dr. Jong Sung (John) Koh, focusing on developing and commercializing novel immunology and oncology treatments to improve the lives of patients. Genosco’s core competence comes from its expertise in generating selective kinase inhibitors that include candidates that ...

Zosano Pharma Corporation

Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing administration of therapeutics to patients using its intracutaneous delivery system, which consists of titanium microneedles coated with drug that can enable rapid systemic administration to patients. The company’s lead product candidate is QtryptaTM (M207), w...

CEL-SCI Corporation CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the h...

Tau Therapeutics LLC

Tau Therapeutics is a clinical stage company developing oncology drugs for solid tumors that selectively inhibit the T-type calcium channel – a novel mechanism of action for cancer. The company’s approach, called Interlaced Therapy™, capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. T-type ...

Dr.ROBERT SCALES

Robert Scales, Ph.D., is a native of Scotland, but he has resided in the Southwest for the past twenty years. He has his doctorate degree in education and he holds a faculty position in the School of Medicine at the University of New Mexico, where he conducts research and teaches motivational interviewing (MI). Currently, he is the Director of Cardiac Rehabilitation and Wellness at a hospital in...

YES

YES is a grassroots organization that provides cancer patients with support, resources, options, education and hope in their fight against liver tumors. It is made up of survivors who have undergone treatment for primary hepatocellular (liver) cancer or liver metastases (cancer that has spread to the liver) from other cancers. For more information ...


More From BioPortfolio on "A Study of RO5045337 in Patients With Solid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks